List view / Grid view
4 April 2017 | By
In this webinar, Anne Goupil-Lamy, Ph.D. from BIOVIA demonstrated, using a case study, the value of bringing real time data together during the project: genomics data, predictive models, and experimental assay data...
22 February 2017 | By James Pound (British Pharmacopoeia)
The British Pharmacopoeia (BP) is a collection of authoritative and publicly available quality standards for medicines, supported by guidance and additional value-adding information. First published in 1864, the BP has an illustrious history that has been built on quality and continually responds to the needs of stakeholders and users.
5 July 2016 | By
Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose...
17 June 2016 | By
Pfizer will invest more than $200 million in the development of the state-of-the-art facility that will enable the production of high-quality, complex biologics...
19 April 2016 | By
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
1 April 2016 | By Chimera Biotec
In this publication Imperacer® case studies demonstrate the advantage of broad assay range combined with excellent sensitivity for several Biologics on their way from R&D to clinics...
23 March 2016 | By
As well as delving into secure data sharing, the speakers from BIOVIA and GSK will discuss implementing the BIOVIA Biological Registration solution. The speakers will highlight the importance of effective IP protection and improved decision-making through an integrated and collaborative platform...
2 February 2016 | By Tecan
Tecan has launched a fully automated affinity purification solution for the extraction of large biomolecules, such as proteins, antibodies and antibody-drug conjugates. This set-up takes advantage of the new Thermo Scientific™ MSIA™ Streptavidin EVO microcolumns, which have been specifically designed for use on Tecan’s proven Freedom EVO® platform. In combination…
22 October 2015 | By
Quantifying and sizing subvisible particles in biopharmaceutical products are crucial aspects of formulation development, stability studies, process development, product release and extended characterisation of the final drug product.
16 October 2015 | By
Largest European Event for Biologics Returns to Lisbon from 2-6 November...
25 September 2015 | By
The British Generic Manufacturers Association, the Association of the British Pharmaceutical Industry (ABPI), and the UK BioIndustry Association (BIA) have joined forces to welcome NHS England’s new publication “What is a biosimilar medicine?”.
30 March 2015 | By UCB
UCB has announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing Supply Chain Initiative (AMSCI), which will result in a £6.2 million grant to support the development of novel biologic treatments.
10 March 2015 | By
The bi-specific antibody format is becoming the preferred antibody modality for current development projects in the pharmaceutical industry. This is due to an unsurpassed increase in functional activity relative to traditional mono-specific monoclonal antibodies, and a breakthrough in manufacturability enabled by novel designs. One such bi-specific format, the TandAb, produces…